{
    "ticker": "RCEL",
    "name": "Regenicin, Inc.",
    "description": "Regenicin, Inc. is a biotechnology company focused on developing and commercializing innovative regenerative medicine therapies. Founded in 2011, Regenicin is dedicated to advancing the field of cell therapy and tissue engineering, with a mission to provide transformative solutions for patients with chronic wounds, burns, and other tissue injuries. The company\u2019s flagship product, the CellMist System, utilizes a proprietary process to isolate and administer a patient\u2019s own stem cells directly to the wound site, promoting natural healing and tissue regeneration. Regenicin's approach aims to reduce the burden of surgical interventions and long recovery times associated with traditional wound care methods. With an expert team of scientists and medical professionals, Regenicin is committed to rigorous clinical research and development, ensuring that its therapies are both effective and safe for patients. The company actively collaborates with healthcare providers and institutions to expand the reach of its innovative solutions, aiming to improve the quality of life for patients facing debilitating injuries or surgical wounds.",
    "industry": [
        "Biotechnology",
        "Regenerative Medicine"
    ],
    "headquarters": "Harrison, New York, USA",
    "founded": "2011",
    "website": "https://www.regenicin.com",
    "ceo": "Dr. David H. Kessler",
    "social_media": {
        "twitter": "https://twitter.com/Regenicin",
        "linkedin": "https://www.linkedin.com/company/regenicin"
    },
    "investor_relations": "https://www.regenicin.com/investor-relations",
    "key_executives": [
        {
            "name": "Dr. David H. Kessler",
            "position": "CEO"
        },
        {
            "name": "Dr. Michael J. Schreiber",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Regenerative Therapies",
            "products": [
                "CellMist System"
            ]
        }
    ],
    "seo": {
        "meta_title": "Regenicin, Inc. | Innovating Regenerative Medicine",
        "meta_description": "Explore Regenicin, Inc., a leader in regenerative medicine focused on cell therapy and tissue engineering. Discover our innovative products and commitment to patient care.",
        "keywords": [
            "Regenicin",
            "Regenerative Medicine",
            "Cell Therapy",
            "Tissue Engineering",
            "Wound Care"
        ]
    },
    "faq": [
        {
            "question": "What is Regenicin known for?",
            "answer": "Regenicin is known for its innovative regenerative medicine therapies, particularly the CellMist System for wound care."
        },
        {
            "question": "Who is the CEO of Regenicin?",
            "answer": "Dr. David H. Kessler is the CEO of Regenicin, Inc."
        },
        {
            "question": "Where is Regenicin headquartered?",
            "answer": "Regenicin is headquartered in Harrison, New York, USA."
        },
        {
            "question": "What products does Regenicin offer?",
            "answer": "Regenicin offers the CellMist System, which utilizes stem cells for regenerative wound care."
        },
        {
            "question": "When was Regenicin founded?",
            "answer": "Regenicin was founded in 2011."
        }
    ],
    "competitors": [
        "AMRN",
        "CALA",
        "NVS",
        "BMY"
    ],
    "related_stocks": [
        "AAPL",
        "GOOGL",
        "AMZN",
        "MSFT"
    ]
}